Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Author/ Professor Chris Trimble Explains Why Reverse Innovation Is “Oxygen,” Not Optional For MNCs: An Interview With PharmAsia News (Part 1 Of 2)

This article was originally published in PharmAsia News

Executive Summary

Authors Chris Trimble and Vijay Govindarajan, professors at The Tuck School of Business at Dartmouth, coined the term ‘reverse innovation’ and recently published a book arguing why MNCs need to incorporate RI systemically into their core competitive strategies. Below, Trimble speaks to PharmAsia News on the topic and how pharma companies can relate to it.

You may also be interested in...



Medical Device Companies Come Up With Creative Solutions To Increase Access To Rural Communities In Asia

HONG KONG - A little less than two years ago, multinational conglomerate GE Healthcare said it would spend up to $6 billion in healthcare innovation through a program dubbed "Healthymagination.

New Approaches To Innovation Needed To Reach Globe's Poor At The "Bottom Of The Pyramid" - And To Fend Off Emerging Competitors Around The World

CAMBRIDGE, Mass. - Life science companies looking to provide healthcare solutions to the poorer, "bottom of the pyramid" - a population reaching more than 600 million people in India alone - should focus on business model innovation as much as on innovative products, according to delegates at the U.S.-India Chamber of Commerce biopharmaceutical and healthcare summit in Cambridge, Mass

Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment

ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC082031

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel